Capecitabine Tablet, Film Coated
FDA Label NDC 51407-640

56 label sections · Submitted to the FDA by Golden State Medical Supply, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Golden State Medical Supply, Inc. for the product Capecitabine (NDC 51407-640). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious adverse reactions or death in patients with complete dpd deficiency and bleeding with concomitant use of vitamin k antagonists, 1.1 colorectal cancer, 1.2 breast cancer, 1.3 gastric, esophageal, or gastroesophageal junction cancer, 1.4 pancreatic cancer, 2.1 evaluation and testing for dpd deficiency before initiating capecitabine tablets, 2.2 recommended dosage for colorectal cancer, 2.3 recommended dosage for breast cancer, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.